Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine-Reference-Cited by-同舟云学术

Long-term progression-free survival in a patient with advanced non-small-cell lung cancer treated with low-dose gefitinib and traditional herbal medicine

Published:2021-02-05 Issue:5 Volume:100 Page:e24292
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Lee Beom-Joon,Kim Kwan-Il,Choi Cheong-Woon,Kim Jong Yeol,Lee Jun-Hwan

Funder

Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference36 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Epidemiology of lung cancer in Korea: recent trends;Park;Tuberc Respir Dis (Seoul),2016

3. Delays in the diagnosis of lung cancer;Ellis;J Thorac Dis,2011

4. Antineoplastic treatment of advanced-stage non-small-cell lung cancer: treatment, survival, and spending (2000 to 2011);Bradley;J Clin Oncol,2017

5. Precision diagnosis and treatment for advanced non–small-cell lung cancer;Reck;N Engl J Med,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Traditional and contemporary herbal medicines in management of cancer: A scoping review;Journal of Ayurveda and Integrative Medicine;2024-01

2. Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model;Frontiers in Pharmacology;2023-05-18

3. A novel RP-HPLC method development and validation for simultaneous quantification of gefitinib and resveratrol in polymeric hybrid lipid nanoparticles and glioma cells;Journal of Chromatography B;2022-12

4. Bojungikki-Tang Enhances the Effect of PD-1 Blockade in a Syngeneic Murine Model of Lung Carcinoma;Processes;2022-08-25

5. Gefitinib;Reactions Weekly;2021-03